Emerging Techniques Bring Diffusion-weighted Imaging of the Breast into Focus

Combining b2500 diffusion-weighted imaging with BI-RADS improves the specificity of breast MRI

PURPOSE

The purpose of this study was to evaluate the diagnostic performance of visual assessment of diffusion-weighted images (DWI) obtained with a b value of 2500 s/mm2 in addition to a conventional magnetic resonance imaging (MRI) protocol to characterize breast lesions.

MATERIALS AND METHODS

This single-institution retrospective study included participants who underwent clinically indicated breast MRI and breast biopsy from May 2017 to February 2020. The examination included a conventional MRI protocol including DWI obtained with a b value of 50 s/mm2 (b50DWI) and a b value of 800 s/mm2 (b800DWI) and DWI obtained with a b value of 2500 s/mm2 (b2500DWI). Lesions were classified using Breast Imaging Reporting and Data Systems (BI-RADS) categories. Three independent radiologists assessed qualitatively the signal intensity within the breast lesions relative to breast parenchyma on b2500DW and b800DWI and measured the b50-b800-derived apparent diffusion coefficient (ADC) value. The diagnostic performances of BI-RADS, b2500DWI, b800DWI, ADC and of a model combining b2500DWI and BI-RADS were evaluated using receiver operating characteristic (ROC) curves analysis.

RESULTS

A total of 260 patients with 212 malignant and 100 benign breast lesions were included. There were 259 women and one man with a median age of 53 years (Q1, Q3: 48, 66 years). b2500DWI was assessable in 97% of the lesions. Interobserver agreement for b2500DWI was substantial (Fleiss kappa = 0.77). b2500DWI yielded larger area under the ROC curve (AUC, 0.81) than ADC with a 1 × 10-3 mm2/s threshold (AUC, 0.58; P = 0.005) and than b800DWI (AUC, 0.57; P = 0.02). The AUC of the model combining b2500DWI and BI-RADS was 0.84 (95% CI: 0.79-0.88). Adding b2500DWI to BI-RADS resulted in a significant increase in specificity from 25% (95% CI: 17-35) to 73% (95% CI: 63-81) (P < 0.001) with a decrease in sensitivity from 100% (95% CI: 97-100) to 94% (95% CI: 90-97), (P < 0.001).

CONCLUSION

Visual assessment of b2500DWI has substantial interobserver agreement. Visual assessment of b2500DWI offers better diagnostic performance than ADC and b800DWI. Adding visual assessment of b2500DWI to BI-RADS improves the specificity of breast MRI and could avoid unnecessary biopsies.

Assessment and Response to Neoadjuvant Treatments in Breast Cancer: Current Practice, Response Monitoring, Future Approaches and Perspectives

Neoadjuvant treatments (NAT) for breast cancer (BC) consist in the administration of chemotherapy-more rarely endocrine therapy-before surgery. Firstly, it was introduced 50 years ago to downsize locally advanced (inoperable) BCs. NAT are now widespread and so effective to be used also at the early stage of the disease. NAT are heterogeneous in terms of therapeutic patterns, class of used drugs, dosage, and duration. The poly-chemotherapy regimen and administration schedule are established by a multi-disciplinary team, according to the stage of disease, the tumor subtype and the age, the physical status, and the drug sensitivity of BC patients. Consequently, an accurate monitoring of treatment response can provide significant clinical advantages, such as the treatment de-escalation in case of early recognition of complete response or, on the contrary, the switch to an alternative treatment path in case of early detection of resistance to the ongoing therapy. Future is going toward increasingly personalized therapies and the prediction of individual response to treatment is the key to practice customized care pathways, preserving oncological safety and effectiveness. To gain such goal, the development of an accurate monitoring system, reproducible and reliable alone or as part of more complex diagnostic algorithms, will be promising.